05B · Claim Check
ERAS-0015 · Erasca AURORAS-1 · NCT06983743
- Readout
- ERAS-0015 · Erasca AURORAS-1 · NCT06983743 (opens another website in a new tab)
- What the registry or primary source says
- Registered as Phase 1. Primaries: dose-limiting toxicities, maximum tolerated dose, recommended dose, adverse events, pharmacokinetics; response rate secondary. N=600 (planned); recruiting; primary completion 05.2028.
- What the headline says
- Confirmed response rate 44% (n=25) in pancreatic cancer at 32 mg; no dose-limiting toxicities
- Verdict
- Partial
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Claim Check